Antibody-drug Conjugates & Bioconjugates
PARTNERING & PIPELINE
Catalent Biologics offers flexible options for our partners to employ SMARTag® technology in their bioconjugate and ADC programs, including broad research licenses, target-specific commercial licenses, co-development / product participation deals, and bundled deals including GPEx® cell line development, antibody manufacturing, and analytical services.
Please click here to inquire about potential SMARTag® collaboration opportunities:
- Licensing an asset from our pipeline (including molecules against both solid and hematopoietic tumors)
- Collaborating with us to develop de novo assets using our SMARTag® platform technology and ADC development expertise
![SMARTag-ADC-Bioconjugate-Pipeline_V3 Chart indicating the SMARTag ADC Bioconjugate pipline from discovery / optimization, to pre-clinical development, to Phase 1.](https://biologics.catalent.com/wp-content/uploads/sites/2/2023/05/SMARTag-ADC-Bioconjugate-Pipeline_V3.png)